This is Derbyshire --
A BURTON-based pharmaceutical giant has been given the green light for its MRSA-beating drug to be used across Europe.
Clinigen, based at the Centrum 100 business park, has said that its global access programs arm has been given approval to provide the anti-bacterial Vibativ to patients in Europe with hospital-acquired bacterial pneumonia.
Suspected to be caused by MRSA, HAP is a condition that is hard to tackle and the new drug will allow physicians to treat people.
Shaun Chilton, Clinigen's chief operating officer, said: "Vibativ is a drug that can be used when other alternatives for HAP are not suitable." Reported by This is 8 hours ago.
A BURTON-based pharmaceutical giant has been given the green light for its MRSA-beating drug to be used across Europe.
Clinigen, based at the Centrum 100 business park, has said that its global access programs arm has been given approval to provide the anti-bacterial Vibativ to patients in Europe with hospital-acquired bacterial pneumonia.
Suspected to be caused by MRSA, HAP is a condition that is hard to tackle and the new drug will allow physicians to treat people.
Shaun Chilton, Clinigen's chief operating officer, said: "Vibativ is a drug that can be used when other alternatives for HAP are not suitable." Reported by This is 8 hours ago.